drugset / Trial / NCT00005047
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
Phase 3
Terminated
521 enrolled
SWOG Cancer Research Network
NCIC Clinical Trials Group · collabNational Cancer Institute (NCI) · collabUniversity of Southern California · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective than observation alone in treating bladder cancer. PURPOSE: This randomized phase III trial is studying combination chemotherapy to see how well it works compared to observation alone in treating patients with bladder cancer.
Timeline
- Start
- 1997-08
- Primary completion
- 2011-03
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Methotrexate | Small molecule | — | Intravenous |
| Subject | Vinblastine | Small molecule | — | Intravenous |